Simeglutide outperforms Tizapatine in reducing the risk of the world's leading deadly disease!
- Share
- Issue Time
- Sep 10,2025
Summary
Cardiovascular disease is the leading cause of death worldwide, resulting in nearly 21 million deaths annually.
In August, Novo Nordisk released key data from the STEER real-world study at the European Society of Cardiology (ESC) conference held in Madrid, Spain.
This study compared Wegovy with overweight/obese patients with confirmed cardiovascular disease (CVD) and without diabetes ® The efficacy of 2.4mg (semaglutide) and tizepatide showed that Wegovy demonstrated outstanding performance in reducing the risk of cardiovascular adverse events.
1、 The advantage of Wegovy in reducing cardiovascular risk is clear. The STEER study validated Wegovy's cardiovascular protective effect through two analysis scenarios: 1 Continuous treatment population (without discontinuation of medication for more than 30 days): Compared with ticagrelor, Wegovy significantly reduces the risk of "heart attack, stroke, or all-cause death" in patients by 57%.
2. For all treatment populations (regardless of whether there is a discontinuation gap): Wegovy still reduces the aforementioned risk by 29%.
The study also pointed out that the cardiovascular benefits of Wegovy are specific to the semaglutide molecule and cannot be generalized to the entire GLP-1 or GIP/GLP-1 receptor agonist class, providing key evidence for its clinical localization.
3、 Common side effects of Wegovy: Wegovy (semaglutide) 2.4mg with black box warning: may cause thyroid tumors (including cancer), contraindicated for patients with a personal/family history of medullary thyroid cancer (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).
Common side effects include nausea, diarrhea, vomiting, constipation, abdominal pain, headache, fatigue, dizziness, abdominal distension, and hypoglycemia that may occur in patients with type 2 diabetes.
It is worth noting that STEER is not Wegovy's first cardiovascular related study, and two previous studies have laid the evidence foundation for it:
Anna Windle, Senior Vice President of Clinical Development at Novo Nordisk, stated.
The results of STEER not only reflect the cardiovascular value of Wegovy beyond weight management, but also supplement key insights into how drugs serve patients in the real world - providing important reference for clinicians to choose treatment plans and improve long-term patient outcomes.
